Merck
HomeProtein Labeling & ModificationProtein Prenyltransferases

Protein Prenyltransferases

Protein prenylation involves attachment of either the 15-carbon farnesyl or 20-carbon geranylgeranyl isoprenoid to conserved carboxyl-terminal cysteine residues of proteins. Three known enzymes catalyze this type of modification; these are termed protein farnesyltransferase (FTase), protein geranylgeranyltransferase type I (GGTase-I), and protein geranylgeranyltransferase Type II (GGTase-II, also known as Rab GGTase). FTase and GGTase-I are quite closely related and utilize similar mechanisms for substrate recognition and catalysis, while GGTase-II is somewhat distinct in both regards. Proteins prenylated by FTase or GGTase I undergo further processing that includes the removal of three C-terminal amino acids by Rce1 protease and the methylation of C-terminal cysteine by isoprenyl cysteine methyltransferase (Icmt).

FTase was the first protein prenyltransferase to be identified. Purified FTase is a heterodimer consisting of a 48 kDa α subunit and a 46 kDa β subunit. The α subunit of FTase was subsequently found to be the same as the α subunit of GGTase-I. To date, approximately 30 proteins have been identified as substrates of FTase in mammalian cells, and they include all four isoforms of Ras proteins, some Ras-related proteins such as Rap2A, RhoB, and Rheb, nuclear lamin B and prelamin A, several proteins involved in visual signal transduction, some γ-subunits of heterotrimeric G proteins and enzymes such as the PRL tyrosine phosphatases and cytosolic phospholipase A(2)γ. Recently, a proteomics method to identify farnesylated proteins has been developed by applying TAS (tagging via substrate) technology.

Most prenylated proteins are modified by the geranylgeranyl isoprenoid. The major enzyme in this regard is GGTase-I, which is also composed of two non-identical subunits, the aforementioned 48 kDa α subunit and a 43 kDa β subunit. Both FTase and GGTase-I catalyze prenylation reactions using either protein or peptide substrates containing the carboxyl-terminal CaaX motifs, so they are also termed CaaX prenyltransferases. Target proteins of GGTase-I include most Ras-related small G proteins such as those in the Rac, Rho, and Rap subfamilies, and most γ-subunits of heterotrimeric G proteins. Crystallographic analysis of FTase and GGTase I has revealed a set of rules that govern their substrate peptide selectivity.

The third member of this protein prenyltransferase family is GGTase-II. This enzyme has two subunits, a 60 kDa α subunit and a 38 kDa β subunit, that comprise its catalytic unit. Unlike FTase and GGTase-I, GGTase-II requires a third polypeptide for activity, this being a 95 kDa protein termed Rab escort protein (REP) that binds the Rab protein substrate and presents it to the catalytic dimer. GGTase-II most likely catalyzes the geranylgeranylation of all Rab proteins, the majority of which terminate in paired cysteine motifs. Furthermore, the enzyme is capable of di-geranylgeranylation, i.e., modifying both cysteine residues at the carboxyl-terminus of an individual Rab protein.

Development of inhibitors of protein prenyltransferases is an active area of research following the finding that oncogenic forms of Ras proteins require farnesylation for their ability to transform cells. Several representative inhibitors of FTase that have been synthesized are listed below and include both substrate analogs and compounds identified from screening programs. Currently, several inhibitors are evaluated in clinical trials as anti-cancer agents and clinical activities have been detected particularly with hematopoietic malignancies and breast cancer. However, these effects are unlikely to be due to the inhibition of Ras, as farnesyltransferase inhibitors fail to inhibit K-Ras4B which becomes alternatively modified by a geranylgeranyl group when its farnesylation is inhibited. Thus, the mechanism of action of farnesyltransferase inhibitors needs to be further investigated. Interest in the development of GGTase-1 inhibitors as therapeutics has also increased of late.

The Table below contains accepted modulators and additional information.

Footnotes

a) -CaaX: Single letter abbreviations for amino acids. "a" residues are undefined
but generally aliphatic.

b) These FTI compounds also inhibit GGTase-I.

Abbreviations

AZD3409: Isopropyl(2S)-2-({2-(4-fluorophenethyl)-5-[({(2S,4S)-4-[(3-pyridinylcarbonyl)sulfanyl]tetrahydro-1H-pyrrol-2-yl}methyl)amino]benzoyl}amino)-4-(methylsulfanyl)butanoate
B581: N-(2(S)(2(R)-Amino-3-mercaptopropylamino)-3-methylbutyl)-Phe-Met-OH
B956: N-[2S,3Z,5S,6E,8R)-8-Amino-9-mercapto-5-(1-methylethyl)-1-oxo-2-(phenylmethyl)-3,6-nonadienyl]- L-methionine
BMS-193269: N-[2-(1H-Imidazol-4-yl)ethyl]-L-valyl-(3S)-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-L-methionine
BMS-214662: (R)-7-Cyano-2,3,4,5-tetrahydro-1-(1H-imidazole-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H,4-benzodiazepine
BMS-225975: (R)-7-Cyano-2,3,4,5-tetrahydro-1-(1H-1-methyl-imidazol-5-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine hydrochloride
FPP: Farnesyl pyrophosphate
FTI-254: N-[4-[[(2R)-2-Amino-3-mercaptopropyl]amino]benzoyl]-L-methionine methyl ester
GGPP: Geranylgeranyl pyrophosphate
GGTI-2147: 4-[[N-(Imidazol-4-yl)methyleneamino]-2-(1-naphthyl)benzoyl]leucine methyl ester
GGTI-298: N-[4-[[(2R)-2-Amino-3-mercaptopropyl]amino]-2-(1-naphthalenyl)benzoyl]-L-leucine methyl ester
L-744,832: (2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2R)-2-Amino-3-mercaptopropyl]amino]-3-methylpentyl]oxy]-1-oxo-3-phenylpropyl]amino]-4-(methylsulfonyl)-butanoic acid-1-methylethyl ester
R115777: (B-6-[Amino(4-chlorophenyl)(1-methyl-1H-imidazole-5-yl)-methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone
REP: Rab-Escort Protein required for activity of this enzyme
SCH-66336: (+)-4-[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]-pyridin-11(R)-yl)-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamide

References

1.
Brunner T, ,Hahn S, Gupta A, Muschel R, McKenna W, Bernhard E. 2003. Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations. Cancer research. 63(18) 5656-68.
2.
Doll R, Kirschmeier P, Bishop W. 2004. Farnesyltransferase inhibitors as anticancer agents: critical crossroads Current opinion in drug discovery & development. 7(4) 478-86.
3.
Gelb MH, Van Voorhis WC, Buckner FS, Yokoyama K, Eastman R, Carpenter EP, Panethymitaki C, Brown KA, Smith DF. 2003. Protein farnesyl and N-myristoyl transferases: piggy-back medicinal chemistry targets for the development of antitrypanosomatid and antimalarial therapeutics. Molecular and Biochemical Parasitology. 126(2):155-163. https://doi.org/10.1016/s0166-6851(02)00282-7
4.
Gibbs JB, Oliff A. 1997. THE POTENTIAL OF FARNESYLTRANSFERASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS. Annu. Rev. Pharmacol. Toxicol.. 37(1):143-166. https://doi.org/10.1146/annurev.pharmtox.37.1.143
5.
Glomset JA, Gelb MH, Farnsworth CC. 1990. Prenyl proteins in eukaryotic cells: a new type of membrane anchor. Trends in Biochemical Sciences. 15(4):139-142. https://doi.org/10.1016/0968-0004(90)90213-u
6.
Kho Y, Kim SC, Jiang C, Barma D, Kwon SW, Cheng J, Jaunbergs J, Weinbaum C, Tamanoi F, Falck J, et al. 2004. A tagging-via-substrate technology for detection and proteomics of farnesylated proteins. Proceedings of the National Academy of Sciences. 101(34):12479-12484. https://doi.org/10.1073/pnas.0403413101
7.
Liang P. 2009. Reaction Kinetics, Catalytic Mechanisms, Conformational Changes, and Inhibitor Design for Prenyltransferases. Biochemistry. 48(28):6562-6570. https://doi.org/10.1021/bi900371p
8.
Nguyen UTT, Goody RS, Alexandrov K. Understanding and Exploiting Protein Prenyltransferases. Chem. Eur. J. of Chem. Bio.. 11(9):1194-1201. https://doi.org/10.1002/cbic.200900727
9.
Hee-Won P, Lorena S B. 1997. Protein farnesyltransferase. Current Opinion in Structural Biology. 7(6):873-880. https://doi.org/10.1016/s0959-440x(97)80160-1
10.
Scott Reid T, Terry KL, Casey PJ, Beese LS. 2004. Crystallographic Analysis of CaaX Prenyltransferases Complexed with Substrates Defines Rules of Protein Substrate Selectivity. Journal of Molecular Biology. 343(2):417-433. https://doi.org/10.1016/j.jmb.2004.08.056
11.
Sebti SM, Hamilton AD. 2000. Farnesyltransferase Inhibitors in Cancer Therapy. https://doi.org/10.1385/1592590136
12.
Tamanoi, F. and Sigman, D.S.. 2001. Protein Lipidation, The Enzymes San Diego, CA Academic Press. Vol.21
13.
Tamanoi F, Gau C, Jiang C, Edamatsu H, Kato-Stankiewicz J. 2001. Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells. CMLS, Cell. Mol. Life Sci.. 58(11):1636-1649. https://doi.org/10.1007/pl00000802
14.
Tello M, Kuzuyama T, Heide L, Noel JP, Richard SB. 2008. The ABBA family of aromatic prenyltransferases: broadening natural product diversity. Cell. Mol. Life Sci.. 65(10):1459-1463. https://doi.org/10.1007/s00018-008-7579-3
15.
Vandermoten S, Haubruge É, Cusson M. 2009. New insights into short-chain prenyltransferases: structural features, evolutionary history and potential for selective inhibition. Cell. Mol. Life Sci.. 66(23):3685-3695. https://doi.org/10.1007/s00018-009-0100-9
16.
Zhang FL, Casey PJ. 1996. Protein Prenylation: Molecular Mechanisms and Functional Consequences. Annu. Rev. Biochem.. 65(1):241-269. https://doi.org/10.1146/annurev.bi.65.070196.001325
17.
Zverina EA, Lamphear CL, Wright EN, Fierke CA. 2012. Recent advances in protein prenyltransferases: substrate identification, regulation, and disease interventions. Current Opinion in Chemical Biology. 16(5-6):544-552. https://doi.org/10.1016/j.cbpa.2012.10.015